Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies - PubMed
5 hours ago
- #Immune reset
- #B cell depletion
- #Autoimmune cytopenia
- Autoimmune cytopenias (AICs) result from autoantibody-mediated destruction of blood cells.
- Current treatments often fail to achieve durable remission, leading to long-term immunosuppression and toxicity.
- B cells and plasma cells play a central role in sustaining disease activity and relapse.
- The concept of 'immune reset' aims for sustained, treatment-free remissions.
- The review examines B cell depletion strategies targeting different maturation stages.
- Therapeutic modalities include monoclonal antibodies, bispecific T cell engagers (TCE), and CAR T cells.
- Key factors for long-term outcomes include depth of depletion, immune reconstitution kinetics, and treatment risks.
- The approach may shift from chronic immunosuppression to durable remissions with time-limited interventions.